An analysis to inform the timing of docetaxel use leveraging data from the United States Veterans Administration on patients with metastatic castration-sensitive prostate cancer (mCSPC).

Authors

Mengxi Zhou

Columbia University Medical Center, New York, NY

Mengxi Zhou , Harshraj Leuva , Rumen Stamatov , Prabhjot Singh Mundi , Yeun-Hee Anna Park , Susan Elaine Bates , Izak Faiena , Antonio Tito Fojo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.

First Author: Gang Chen

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.

First Author: Martin W. Schoen

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results.

First Author: Arun Azad

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study.

First Author: Richard M. Lee-Ying